AC Immune to Present at Jefferies Global Healthcare Conference 2026
AC Immune: Q3 Earnings Snapshot
AC Immune Third Quarter 2026 Financial and Corporate Update
AC Immune Q3 EPS $(0.16) Beats $(0.22) Estimate, Sales $3.994M Beat $1.000M Estimate
AC Immune Parkinson’s Vaccine Study Meets Safety, Immunogenicity Goals
AC Immune Says Investigational Parkinson’s Drug Shows 100% Antibody Response
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
AC Immune Announces Safety And Immunogenicity Results Through Week 100 In Part 1 Of VacSYn, Its Phase 2 Trial Of ACI-7104 In Patients With Early-Stage Parkinson’s Disease: All Primary Endpoints Were Met, Generally Safe And Well Tolerated; Strong Immunogenicity Demonstrated, With 100% Response Rate After Three Immunizations
AC Immune shares rise after encouraging early Phase 1 data for ACI-19764
AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
BTIG Reiterates Buy on AC Immune, Maintains $8 Price Target
ACIU Stock Heads For Best Day In Over 10 Months On FDA Fast Track Nod For Parkinson’s Disease Therapy – Retail Sees ‘Breakout Soon’
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
AC Immune (ACIU) Beats Q2 Earnings and Revenue Estimates
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
AC Immune Announces Three Presentations At The Alzheimer's Association International Conference, July 12-15
AC Immune: Holding Into A Make-Or-Break H2 2026 Readout
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.